Pivekimab sunirine

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NamePivekimab sunirine
Drug Alias NamePivekimab-IGNIMGN-632
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Ala-Ala dipeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAlkylating agentsInterleukin-3 receptor subunit alpha inhibitorsDNA inhibitors
TargetsInterleukin-3 receptor subunit alphaDNA
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative DisordersMyelodysplastic Syndromes +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany +[6] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesImmunogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncJazz Pharmaceuticals Plc
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative DisordersMyelodysplastic Syndromes +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG